Therapy Areas: Cardiovascular
The US Food and Drug Administration approves Alnylam Pharmaceuticals' Onpattro
14 August 2018 -

The US Food and Drug Administration (FDA) has approved United States-based Alnylam Pharmaceuticals' RNA interference therapeutic, Onpattro (patisiran) lipid complex injection, intended to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, it was reported yesterday.

The product is claimed to be the first-of-its-kind RNAi therapeutic and only FDA-approved treatment for this indication. The product had previously received breakthrough therapy and orphan drug designations from the US FDA.

The approval was based on results from the randomized, double-blind, placebo-controlled and global phase 3 Apollo study. In the study, the safety and efficacy of Onpattro was assessed in a diverse global population of hATTR amyloidosis patients in 19 countries, with a total of 39 TTR mutations. The primary endpoint of the trial was the modified neuropathy impairment Score +7 (mNIS+7), which evaluated motor strength, reflexes, sensation, nerve conduction and postural blood pressure.

The hATTR amyloidosis is a rare, inherited and life-threatening disease that will also cause significant disabilities including decreased ambulation with the loss of the ability to walk unaided, reduced quality of life and decline in cardiac functioning.



Related Headlines